These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17673939)

  • 21. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Maynadier M; Basile I; Gallud A; Gary-Bobo M; Garcia M
    Oncol Rep; 2016 Aug; 36(2):1127-34. PubMed ID: 27373750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of zinc transporters by dietary flaxseed lignan in human breast cancer xenografts.
    Zhang LY; Wang XL; Sun DX; Liu XX; Hu XY; Kong F
    Mol Biol Rep; 2008 Dec; 35(4):595-600. PubMed ID: 17786585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
    Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
    Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
    Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
    Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.
    Gomez BP; Riggins RB; Shajahan AN; Klimach U; Wang A; Crawford AC; Zhu Y; Zwart A; Wang M; Clarke R
    FASEB J; 2007 Dec; 21(14):4013-27. PubMed ID: 17660348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
    Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
    Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.
    Alam MW; Persson CU; Reinbothe S; Kazi JU; Rönnstrand L; Wigerup C; Ditzel HJ; Lykkesfeldt AE; Påhlman S; Jögi A
    Oncotarget; 2016 Mar; 7(10):11238-50. PubMed ID: 26849233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
    Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
    Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zinc Transporters and the Progression of Breast Cancers.
    Takatani-Nakase T
    Biol Pharm Bull; 2018; 41(10):1517-1522. PubMed ID: 30270320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
    Pennanen PT; Sarvilinna NS; Ylikomi TJ
    Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
    Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
    Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.